To prevent surgery-related shortcomings, several non-surgical (e.g. mechanical) and enzymatic debriding means are still used but all are inefficiently slow and may involve eschar and wound-handling complications.
NexoBrid™ significantly reduces time to successful eschar removal allowing treatment to progress to the next stage of wound closure more rapidly.
The efficacy of NexoBrid™ at removing eschar is achieved without the “collateral damage” of harming the surrounding viable tissues, mainly the dermis.
MediWound’s flagship innovative drug, NexoBrid™, is indicated for the removal of eschar in adults with deep partial- and full-thickness thermal burns, a process also known as debridement. > Read More
This website is designated solely for the use of physicians / pharmacists / nurses qualified to work in their professions in their country.